About: Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
Creator	Fallarino, Francesca Amirhossein Sahebkar, · Bianconi, Vanessa Pignatelli, Pasquale Pirro, Matteo Violi, Francesco
Source	Medline; PMC
abstract	Severe Acute Respiratory Syndrome–Coronavirus-2 is responsible for the current pandemic that has led to more than 10 million confirmed cases of Coronavirus Disease-19 (COVID-19) and over 500,000 deaths worldwide (4 July 2020). Virus-mediated injury to multiple organs, mainly the respiratory tract, activation of immune response with the release of pro-inflammatory cytokines, and overactivation of the coagulation cascade and platelet aggregation leading to micro- and macrovascular thrombosis are the main pathological features of COVID-19. Empirical multidrug therapeutic approaches to treat COVID-19 are currently used with extremely uncertain outcomes, and many others are being tested in clinical trials. Acetylsalicylic acid (ASA) has both anti-inflammatory and antithrombotic effects. In addition, a significant ASA-mediated antiviral activity against DNA and RNA viruses, including different human coronaviruses, has been documented. The use of ASA in patients with different types of infections has been associated with reduced thrombo-inflammation and lower rates of clinical complications and in-hospital mortality. However, safety issues related both to the risk of bleeding and to that of developing rare but serious liver and brain damage mostly among children (i.e., Reye’s syndrome) should be considered. Hence, whether ASA might be a safe and reasonable therapeutic candidate to be tested in clinical trials involving adults with COVID-19 deserves further attention. In this review we provide a critical appraisal of current evidence on the anti-inflammatory, antithrombotic, and antiviral effects of ASA, from both a pre-clinical and a clinical perspective. In addition, the potential benefits and risks of use of ASA have been put in the context of the adult-restricted COVID-19 population.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1007/s40265-020-01365-1
bibo:pmid	32705604
has license	cc-by-nc
sha1sum (hex)	cf89bc4e8a5195110dc7deab61de14007df14867
schema:url	https://doi.org/10.1007/s40265-020-01365-1
resource representing a document's title	Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19 ?
has PubMed Central identifier	PMC7376326
has PubMed identifier	32705604
schema:publication	Drugs
resource representing a document's body	covid:cf89bc4e8a5195110dc7deab61de14007df14867#body_text
is schema:about of	named entity 'thrombosis' named entity 'current' named entity 'pandemic' named entity 'Acute' named entity 'COVID-19' named entity 'extremely' named entity 'Coronavirus' named entity 'However' named entity 'rare' named entity 'antithrombotic' named entity 'CANDIDATE' named entity 'CLINICAL TRIALS' named entity 'ACTIVATION OF IMMUNE RESPONSE' named entity 'APPRAISAL' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME' named entity 'CURRENT' covid:arg/cf89bc4e8a5195110dc7deab61de14007df14867 named entity 'led' named entity 'immune response' named entity 'multiple' named entity 'injury' named entity 'Respiratory' named entity 'coagulation cascade' named entity 'Severe Acute Respiratory Syndrome' named entity 'thrombosis' named entity 'immune response' named entity 'therapeutic approaches' named entity 'inflammation' named entity 'Acetylsalicylic acid' named entity 'liver' named entity 'COVID-19' named entity 'low molecular-weight heparin' named entity 'H1N1 virus' named entity 'leukocyte' named entity 'gastrointestinal tract' named entity 'cesarean delivery' named entity 'HIV' named entity 'COVID' named entity 'C/EBP' named entity 'dysgeusia' named entity 'antipyretic' named entity 'superoxide dismutase' named entity 'viral RNA' named entity 'disseminated intravascular coagulation' named entity 'risk ratio' named entity 'mice' named entity 'platelet' named entity 'fibrinogen' named entity 'antithrombotic' named entity 'pathophysiological' named entity 'iNOS' named entity 'analgesic' named entity 'SARS-CoV-2' named entity 'acute respiratory infections' named entity 'plasma' named entity 'platelet aggregation' named entity 'randomized clinical trials' named entity 'case-control study' named entity 'intravascular coagulation' named entity 'HIV' named entity 'vaccine' named entity 'venous thromboembolism' named entity 'Reye's syndrome' named entity 'PGI2' named entity 'flu symptoms' named entity 'inflammation' named entity 'flu' named entity 'anticoagulants' named entity 'long-term' named entity 'gastrointestinal bleeding' named entity 'metabolite' named entity 'sepsis' named entity 'thrombi' named entity 'infection' named entity 'heparin' named entity 'COX-1 and COX-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software